Literature DB >> 9131262

Estrogens and atherosclerosis.

L Nathan1, G Chaudhuri.   

Abstract

Estrogens prevent heart disease in women and have also been shown to retard atherogenesis in animal models. Estrogens may act at several steps in the atherogenic process to prevent cardiovascular disease. Some of the benefits of estrogens can be ascribed to their ability to favorably alter the lipoprotein profile, i.e. increase high-density lipoprotein and decrease low-density lipoprotein, and also to their ability to prevent oxidative modification of low-density lipoprotein. Other beneficial effects of estrogens include direct actions on the vascular endothelium and vascular smooth muscle, leading to a decrease in the expression of adhesion molecules involved in monocyte adhesion to endothelial cells, and to a decrease in certain chemokines involved in monocyte migration into the subendothelial space. Estrogens may also affect the later stages of atherogenesis. Finally, estrogens may modify the behavior of atherosclerotic vessels by altering their reactivity and thereby promoting vasodilation, and this may also partly account for their ability to prevent clinical events due to cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131262     DOI: 10.1146/annurev.pharmtox.37.1.477

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  28 in total

1.  Gender differences in food insecurity and morbidity among adolescents in southwest Ethiopia.

Authors:  Tefera Belachew; Craig Hadley; David Lindstrom; Abebe Gebremariam; Kifle Wolde Michael; Yehenew Getachew; Carl Lachat; Patrick Kolsteren
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

2.  Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis.

Authors:  Tapan K Mukherjee; Hillary Dinh; Gautam Chaudhuri; Lauren Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  Perinatal Bisphenol A Exposure Increases Atherosclerosis in Adult Male PXR-Humanized Mice.

Authors:  Yipeng Sui; Se-Hyung Park; Fang Wang; Changcheng Zhou
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

4.  Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice.

Authors:  J B Hodgin; J H Krege; R L Reddick; K S Korach; O Smithies; N Maeda
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE-/- Mice.

Authors:  Laura G Goetz; Ramanaiah Mamillapalli; Cagdas Sahin; Masoumeh Majidi-Zolbin; Guanghao Ge; Arya Mani; Hugh S Taylor
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

Review 6.  Sex differences in stroke.

Authors:  Roy A M Haast; Deborah R Gustafson; Amanda J Kiliaan
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-03       Impact factor: 6.200

7.  β-ESTRADIOL INDUCES CYTOTOXIC EFFECTS TO HUMAN T-LYMPHOMA (JURKAT) CELLS THROUGH OXIDATIVE STRESS.

Authors:  Clement Yedjou; Joseph Cameron; Ariane T Mbemi; Paul Tchounwou
Journal:  J Miss Acad Sci       Date:  2015-04

8.  Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice.

Authors:  ZhongMao Guo; Qitao Ran; L Jackson Roberts; Lichun Zhou; Arlan Richardson; Chakradhari Sharan; DongFan Wu; Hong Yang
Journal:  Free Radic Biol Med       Date:  2007-10-02       Impact factor: 7.376

9.  Gender Disparities among Intracerebral Hemorrhage Patients from a Multi-ethnic Population.

Authors:  Alexandra Galati; Sage L King; Kazuma Nakagawa
Journal:  Hawaii J Med Public Health       Date:  2015-09

Review 10.  Nitric oxide and coronary vascular endothelium adaptations in hypertension.

Authors:  Andrew S Levy; Justin C S Chung; Jeffrey T Kroetsch; James W E Rush
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.